{"entity":{"id":"nct07049926","kind":"trial","name":"Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (","aka":[],"tldr":"A phase 1/2 trial of Belzutifan, Zanzalintinib in renal cell carcinoma, run by Merck Sharp & Dohme LLC, now recruiting.","summary":"Substudy 03C: A Study of Combination Therapies in Participants With Renal Cell Carcinoma With Recurrent Disease During or After Anti-PD-(L)1 Therapy (MK-3475-03C/KEYMAKER-U03) is a phase 1/2 interventional study registered as NCT07049926 by Merck Sharp & Dohme LLC, with 140 participants planned, started 2025-07-20 and due to reach its primary completion in 2031-10-26. Interventions recorded: Belzutifan, Zanzalintinib. Conditions listed: Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07049926","url":"https://clinicaltrials.gov/study/NCT07049926"}],"tags":["ctgov-ingest"],"related":[],"cancers":["rcc"],"sections":[],"technologies":[],"targets":[],"drugs":["belzutifan","zanzalintinib"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07049926","phase":"1/2","setting":"A Phase 1b/2 Study of Immune and Targeted Combination Therapies in Participants With RCC (KEYMAKER-U03): Substudy 03C in Participants With Recurrent Disease During or After Anti-PD-(L)1 Adjuvant Therapy","sponsor":"Merck Sharp & Dohme LLC","enrolled":140,"outcomes":[]},"route":"/trials/nct07049926/","neighbours":{"cancer":[{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"}],"drug":[{"id":"belzutifan","kind":"drug","name":"Belzutifan","route":"/drugs/belzutifan/"},{"id":"zanzalintinib","kind":"drug","name":"Zanzalintinib","route":"/drugs/zanzalintinib/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}